Tahara J, et al. - Researchers performed a retrospective analysis of patients with locally advanced and metastatic pancreatic cancer who were treated with either FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) as first-line therapy at their hospital between March 2014 and April 2017. They assessed the clinical characteristics, survival outcomes and adverse events and found that in the G-nab group vs in the FFX group, the disease control rate was 86.7% vs 75%, the observed median OS time was 11.8 months vs 8.9 months, and the observed 1-year survival rate was 46.6% vs 16.6%. Overall, they concluded that although both treatment options are effective for advanced pancreatic cancer G-nab group provided a higher 1-year survival rate and could be more safely administered to older patients.